Preventing relapse after stem cell transplant for high-risk MDS
Part of Blood & lymphatic clinical trials.
This trial tests whether giving medication after a donor stem cell transplant can prevent the return of very high-risk myelodysplastic syndrome (MDS). It is for people who have a suitable donor and are healthy enough for the procedure.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have been diagnosed with very high-risk MDS using a scoring system called IPSS-M.
- You have a stem cell donor who is a good match (related donor at least half-match, unrelated donor at least 80% match).
- You are generally healthy with good liver, kidney, heart, and lung function.
- You are able to give written informed consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new approach to reduce the chance of leukemia or other blood cancers coming back after a stem cell transplant. It uses careful monitoring before the transplant to try to prevent relapse.
This study tests whether a medication called IFN-α can help prevent the blood cancer from coming back after a stem cell transplant. It is for people with certain types of blood cancers who are at high risk of relapse.
This trial tests a combination of three drugs (vedolizumab, cyclophosphamide, and tacrolimus) to prevent graft-versus-host disease, a common complication after a donor stem cell transplant. It is for people with certain blood cancers who are getting a reduced-intensity transplant.
This trial uses donor immune cells (lymphocytes) after a stem cell transplant to help fight any remaining cancer in people with high-risk blood cancers. It aims to lower the chance of the cancer coming back.
This trial tests adding a drug called emapalumab to standard medications (cyclophosphamide, tacrolimus, mycophenolate mofetil) to prevent graft-versus-host disease in adults receiving a donor stem cell transplant. This approach aims to reduce complications after transplant.
This study tests whether giving specially treated donor immune cells after a stem cell transplant can help prevent relapse in patients with high-risk blood cancers. You would get a stem cell transplant from a relative, followed by an infusion of donor cells that have been processed to reduce the risk of graft-versus-host disease.
Hear when a new Myelodysplastic Syndromes, Adult trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.